Ajay Tuli, MD
Interventional Cardiology · Tucson, AZNPI 1093793267
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,044 of the $14,312 with a category attached, or 84.2%. It is spread thinly across 33 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,669 and has fallen 78.2% since, to $1,019 in 2025.
Across 941 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$2K
- Biotronik Inc.$2K
- Novartis$1K
- Abbott$1K
- Canon Medical Systems USA, Inc.$1K
- Pfizer$927
- plus $6K from 27 others
Across 18 payments — averaging $40,947 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$470K
- Novartis$198K
- Amgen$69K
What the payments were for
- Grants$250%
- Travel & lodging$2,24316%
- Food & beverage$12,04484%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 86 | $1,983 |
| Biotronik Inc. | 6 | $1,518 |
| Novartis | 184 | $1,413 |
| Abbott | 191 | $1,340 |
| Canon Medical Systems USA, Inc. | 3 | $1,085 |
| Pfizer | 76 | $927 |
| Johnson & Johnson | 135 | $860 |
| Actelion Pharmaceuticals US, Inc. | 56 | $686 |
| E.r. Squibb & Sons, L.L.C. | 36 | $496 |
| Amgen | 43 | $479 |
| Merck | 21 | $405 |
| Boston Scientific | 12 | $325 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $312 |
| Cvrx, Inc. | 9 | $303 |
| Edwards Lifesciences | 4 | $282 |
| ZOLL Respicardia, Inc. | 1 | $239 |
| Medtronic(2 entities) | 4 | $210 |
| Philips North America LLC | 4 | $199 |
| Bayer | 4 | $174 |
| Kowa Pharmaceuticals America, Inc. | 2 | $154 |
| AstraZeneca | 9 | $150 |
| Impulse Dynamics (USA) Inc. | 2 | $134 |
| Inspire Medical Systems, Inc. | 1 | $117 |
| Astellas Pharma US Inc | 7 | $93 |
| Boehringer Ingelheim | 5 | $92 |
| Amarin Pharma, Inc. | 5 | $84 |
| Esperion Therapeutics, Inc. | 5 | $79 |
| Sanofi-aventis U.S. LLC | 4 | $53 |
| Novo Nordisk | 2 | $44 |
| Bridgebio Pharma, Inc. | 1 | $21 |
| Cordis US CORP. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$930
- UPTRAVI$255
- OPSUMIT$255
- remede System$239
- OPTIMIZER$221
- Barostim Neo System$149
- Fortify Assura, Ellipse ICD$139
- Livalo$136
- SAPIEN 3 Ultra RESILIA$133
- Kerendia$133
- Inspire Upper Airway Stimulation System$117
- ONYX FRONTIER$112
- Assurity Pacemaker$102
- LEQVIO$101
How this compares
$14,312 in reported general payments places this provider in the 55th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 56 | $2,029,980 |
| EliquisApixaban | 1,272 | $1,734,123 |
| XareltoRivaroxaban | 975 | $1,285,427 |
| EntrestoSacubitril/Valsartan | 458 | $646,387 |
| FarxigaDapagliflozin Propanediol | 229 | $295,642 |
| Repatha SureclickEvolocumab | 169 | $202,354 |
| JardianceEmpagliflozin | 111 | $158,914 |
| MultaqDronedarone Hcl | 32 | $67,739 |
| Praluent PenAlirocumab | 34 | $34,466 |
| VascepaIcosapent Ethyl | 28 | $27,141 |
| Flecainide Acetate | 334 | $16,695 |
| BrilintaTicagrelor | 12 | $15,224 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 41 | $13,753 |
| Nebivolol Hcl | 200 | $13,384 |
| Ezetimibe | 579 | $11,854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $927 | $3,764,1031,328 claims |
| Johnson & JohnsonXarelto | $860 | $1,285,427975 claims |
| NovartisEntresto | $1,413 | $646,387458 claims |
| AstraZenecaFarxiga, Brilinta | $150 | $310,866241 claims |
| Boehringer IngelheimJardiance | $92 | $158,914111 claims |
| Sanofi-aventis U.S. LLCMultaq | $53 | $67,73932 claims |
| BayerKerendia | $174 | $7,62412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Tucson
- Thomas WaggonerTucson$617K
- Kapildeo LotunTucson$365K
- Neil GheewalaTucson$141K
- Dexter de LeonTucson$74K
- William ThomasTucson$56K
- Ranjith ShettyTucson$50K
- Santiago RamirezTucson$45K
- Sulaiman RathoreTucson$32K
- Michel CorbanTucson$27K
- Sundeep ShenoyTucson$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.